Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Aggression × Rituximab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 56 Lymphoma, Large B-Cell, Diffuse 46 Lymphoma 46 Lymphoma, Non-Hodgkin 44 Lymphoma, Follicular 35 Lymphoma, Mantle-Cell 26 Lymphoma, B-Cell 23 Lymphoma, B-Cell, Marginal Zone 22 Precursor Cell Lymphoblastic Leukemia-Lymphoma 18 Leukemia 18 Burkitt Lymphoma 17 Waldenstrom Macroglobulinemia 14 Recurrence 13 Hodgkin Disease 12 Multiple Myeloma 8 Lymphoma, Large-Cell, Immunoblastic 7 Leukemia, Myeloid, Acute 7 Neoplasms, Plasma Cell 6 Leukemia, Prolymphocytic 6 Hematologic Neoplasms 6 Myelodysplastic Syndromes 5 Neoplasms 4 Leukemia, Hairy Cell 4 Lymphoma, T-Cell 3 Leukemia, Myeloid, Chronic-Phase 3 Intraocular Lymphoma 3 Neoplasm Metastasis 2 Myeloproliferative Disorders 2 Mycosis Fungoides 2 Lymphoma, T-Cell, Peripheral 2

Interventions

selinexor 1 Rituximab 1 Ifosfamide 1 Etoposide 1 Dexamethasone 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02471911 2022-04-12

KPT-330+RICE

Weill Medical College of Cornell University

Phase 1 Completed

Aggression, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡